Education
About Us
Working with TipRanks
Follow Us
Entera Bio Ltd (ENTX)
NASDAQ:ENTX
ENTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.41 - $3.35
Previous CloseN/A
Volume29.71K
Average Volume (3M)56.19K
Market Cap
$78.46M
Enterprise Value$64.84M
Total Cash (Recent Filing)$7.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Mar 27, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding41,735,450
10 Day Avg. Volume48,236
30 Day Avg. Volume56,188
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)725.48
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.16K
Enterprise Value/Ebitda-7.08
Forecast
1Y Price Target
$10.00Price Target Upside449.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Entera Bio News
PremiumPre-Earnings
Entera Bio (ENTX) Q4 Earnings Cheat Sheet
PremiumCompany Announcements
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon
PremiumCompany Announcements
Entera Bio Highlights Q3 2024 Financials and FDA Anticipation
---
Bulls Say, Bears Say
Bulls Say
Collaboration And FundingThe collaboration with OPKO provides access to a promising anti-obesity candidate, funding, and favorable economics in a large and lucrative market.
Regulatory DevelopmentsThe anticipated FDA ruling on the SABRE ASBMR-FNIH regulatory endpoint could significantly mitigate risks for Entera's EB613, paving the way for its advancement.
Bears Say
Development RisksRisks include failure to advance EB613 or EB612 through clinical development in a timely manner and inability to secure a partner to optimize the commercial value of EB613.
Financial PerformanceEntera reported a net loss per share mainly driven by higher than expected operating expenses.
---
Ownership Overview
2.66% Insiders
0.05% Mutual Funds
1.65% Other Institutional Investors
95.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $1.41 and its highest was $3.35 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $78.46M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Mar 27, 2025 which is today.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on Nov 08, 2024. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.03.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.08.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 41,735,450 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -1.163%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
---
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (449.45% Upside)
$10.00 (449.45% Upside)
Blogger Sentiment
Bullish
ENTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 296.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.51%
12-Months-Change
Fundamentals
Return on Equity
-144.67%
Trailing 12-Months
Asset Growth
-9.62%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
---
ENTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(449.45% Upside)
Technical Analysis
Best Analysts Covering ENTX
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+47.11%
reiterated a buy rating 10 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +47.11% per trade.
---